Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors
Status:
Recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
This is a prospective single arm, multicenter study will evaluate the efficacy and safety of
Lutetium-177 Octreotate in patients with neuroendocrine tumors who has positive Somatostatin
receptor identified by 68Ga-DOTATATE. 195 patients will be enrolled totally. Patient who has
progressed with neuroendocrine tumor will be evaluated by the tumor board first and eligible
patients will undergo diagnostic Ga 68 PET scan. Patients who showed Somatostatin will
undergo 4 cycles of Lu-DOTATATE treatment. Dose adjustment for Cycle 2-4 will be made based
on individualized dosimetry, as well as creatinine clearance and hematological parameters.
Patients will be evaluated progression free survival at 12 months from last dose. Patients
who are negative for somatostatin will not receive 68Ga-DOTATATE treatment but will be
followed until progression and acts as control group.
Phase:
N/A
Details
Lead Sponsor:
University Health Network, Toronto
Collaborators:
Canadian Molecular Imaging Probe Consortium Cancer Care Ontario Ozmosis Research Inc.